Russia is selling millions of doses of its domestic Sputnik V vaccine overseas, making it a major supplier of a shot that could give Moscow a valuable slice of the global Kovid-19 vaccine market, and potentially Russia in the developing world. Can get geopolitical benefits.
Argentina is the first major country outside Russia to begin vaccination with Sputnik. However, the rollout has raised questions about the lack of transparency regarding the efficacy of state-sponsored Sputnik V, which has led to some mistrust among Argentina about its safety.
Moscow approved Sputnik V in August before finishing the trial for domestic use. Trial data released since then showed that Sputnik was 91.4% effective in protecting people from Kovid-19, and a peer-reviewed study is expected to be published in the coming weeks. Nearly one lakh Russians have received the shot.
Other countries have run to buy vaccines that are cheaper than western alternatives. Sputnik V, named for the Soviet satellite during the Cold War, launched in orbit during the Cold War, according to Duke University’s Global Health Innovation Center, America’s drugmaker Polyiser Inc., by middle and low-income countries. Ordered ranks third in the world. Modern Ink and China’s Vaccines. Eight countries outside Russia have authorized the shot for emergency use.
Nevertheless, Sputnik V has not been approved by Western health authorities or obtained authorization from the World Health Organization, which many developing countries rely on for vaccines. Russia has initiated negotiations with the European Medical Agency and applied for WHO authorization about approving the shot in the European Union.